Martin Shkreli fired from another pharma company after arrest

He then started another drug company, Turing Pharmaceuticals, and where he made headlines by hiking the price of a life-saving drug by more than 5,000%.

On Thursday last week, Shkreli faced charges of securities fraud, securities fraud conspiracy and wire fraud conspiracy in relation to a previous hedge fund endeavor.

KaloBios said Monday that it terminated Shkreli last Thursday, but it did not give a reason. One board member who came in with Shkreli, Tony Chase, also resigned, the company said.

Shkreli has often used Twitter to parry with critics, project what some call a “pharma-bro” persona-which includes a love of hip-hop that led him to buy an unreleased Wu-Tang Clan album for $2 million-and even make industry connections.

The KaloBios ouster marks the latest setback for the 32-year-old healthcare industry entrepreneur who has drawn widespread criticism for imposing steep price hikes in the cost of drugs controlled by his companies.

“That seems like a real injustice”, he told the Wall Street Journal, adding that he took offense at the U.S. Attorney referencing his actions as a “Ponzi-like scheme”.

In a separate incident, on Sunday, Martin Shkreli had lost control of his Twitter account to hackers, hours after he took to Twitter to plead his innocence, his spokesman said. “Willing to donate hundreds of thousands to charities before I go to prison…” and, “I am now a god”. The SEC complaint accuses Shkreli of a string of abuses, including exaggerating to hedge-fund investors his investment performance and assets under management.

Shkreli, who has become the poster child for the issue of soaring prices for prescription medications, has already stepped down as CEO of private drugmaker Turing Pharmaceuticals Inc, in addition to resigning from KaloBios’ board of directors.

“I am confident I will prevail” against the charges, he tweeted Saturday.

The firing comes just one month after he assumed the role, according to a statement released by the company on Monday. Kalobios shares rose from less than a $1 to a high of almost $40 under his brief leadership, but its stocks have stopped trading in the wake of Shkreli’s legal drama.